Enhanced oral bioavailability of the antiretroviral efavirenz encapsulated in poly(epsilon-caprolactone) nanoparticles by a spray-drying method.

Simple item page
dc.creatorTshweu, Lesego
dc.creatorKatata, Lebogang
dc.creatorKalombo, Lonji
dc.creatorChiappetta, Diego
dc.creatorHocht, Christian
dc.creatorSosnik, Alejandro
dc.creatorSwai, Hulda
dc.date2019-10-16T08:24:47Z
dc.date2019-10-16T08:24:47Z
dc.date2014-10-17
dc.date.accessioned2022-10-25T09:20:42Z
dc.date.available2022-10-25T09:20:42Z
dc.descriptionResearch Article published by NANOMEDICINEVOL. 9, NO. 12
dc.descriptionAim: To encapsulate efavirenz (EFV) within poly(epsilon-caprolactone) (PCL) nanoparticles (NPs) and compare the oral pharmacokinetics with that of EFV-loaded micelles and pure EFV NPs. Materials & methods: EFV-loaded PCL NPs were produced by a double-emulsion/spray-drying method. Results: NPs displayed a hydrodynamic diameter of 200–250 nm. The encapsulation efficiency was 86–93% and the mass recovery was above 60%. X-ray diffraction indicated that drug and PCL underwent amorphization during the spray-drying process. Encapsulation within NPs significantly increased the maximum concentration in plasma and the bioavailability. Conclusion: EFV-loaded PCL NPs represent a promising platform to develop scalable pharmaceuticals with improved (bio)pharmaceutic performance.
dc.formatapplication/pdf
dc.identifier1748-6963
dc.identifier24364871
dc.identifierhttps://doi.org/10.2217/nnm.13.167
dc.identifierhttp://dspace.nm-aist.ac.tz/handle/123456789/491
dc.identifier.urihttp://hdl.handle.net/123456789/95159
dc.languageen
dc.publisherNANOMEDICINE
dc.subjectHIV
dc.subjectEfavirenz
dc.subjectIn vitro drug release
dc.subjectOral bioavailability enhancement
dc.subjectPoly(epsilon-caprolactone) nanoparticle
dc.subjectSpray drying
dc.titleEnhanced oral bioavailability of the antiretroviral efavirenz encapsulated in poly(epsilon-caprolactone) nanoparticles by a spray-drying method.
dc.typeArticle

Files

Collections

Research Articles [LISBE]